Andrew Miller Joins Elucid as Chief Technology Officer

Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead the technological strategy and oversee the engineering team's execution. Elucid's software is the only FDA-cleared non-invasive tool able to accurately characterize arterial plaque, simulating what pathologists would see under a microscope and establishing a histologic ground truth. Elucid is also pursuing an indication for FFR_CT, uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia.

"We're thrilled to welcome Andrew as CTO. He has an incredible technological skillset and proven track record in building high-performing technology teams across numerous successful organizations throughout his career," said Blake Richards, chief executive officer, Elucid. "A true thought leader, his expertise executing vision and growing organizations will help propel Elucid as we grow commercially and realize the next phase of our mission to provide comprehensive and accurate clinical insights that enable unprecedented precision healthcare for vascular disease."

Miller is a health technology veteran with an acumen for transforming startups and growth-stage companies into mature organizations. His proven history of building diverse, high-performing organizations has led to profitable business and acquisition. He joins Elucid from Engooden Health, where he served as CTO and chief information security officer, responsible for delivery of technology solutions and infrastructure supporting the SaaS and service-based organization in its mission to redefine chronic care management. Prior to his leadership role at Engooden, Miller served as vice president of engineering for Curaspan, a naviHealth company. Previously, he held roles at Oracle as a senior leader in its Health Sciences division, and Phase Forward, among others.

Miller joins recent hires Dr. Todd Villines, chief medical officer, and Scott Burger, chief commercial officer, on Elucid's leadership team.

"Elucid offers an exciting opportunity that allows me to leverage my experience and skills to work with the talented team already assembled to achieve our goals," said Miller. "Along with Blake and the rest of the leadership team, I am ready to roll up my sleeves and ensure the company's groundbreaking technology is developed and advanced in a way that fits seamlessly into physician workflow in the most elegant and useful way possible to help solve one of the biggest challenges facing healthcare today."

About Elucid

Elucid is a Boston-based medical technology company dedicated to bringing precision patient care, as currently practiced in oncology, to cardiology. Its AI-powered imaging analysis software is designed to deeply understand the root cause of cardiovascular disease. Elucid's plaque analysis software is powered by PlaqueIQ, the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against tens of thousands of tissue samples by renowned pathologists. Elucid is also pursuing an indication for FFR_CT, uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia. PlaqueIQ equips physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke. The Elucid plaque analysis software is available for commercial use in the U.S. and South Korea. For more information, visit elucid.com.